Int J Biol Sci 2022; 18(12):4714-4730. doi:10.7150/ijbs.72709 This issue

Research Paper

Targeting ACLY efficiently inhibits SARS-CoV-2 replication

Terrence Tsz-Tai Yuen1,*, Jasper Fuk-Woo Chan1,2,3,4,5,6,*, Bingpeng Yan1,*, Cynthia Cheuk-Ying Shum1, Yuanchen Liu1, Huiping Shuai1, Yuxin Hou1, Xiner Huang1, Bingjie Hu1, Yue Chai1, Chaemin Yoon1, Tianrenzheng Zhu1, Huan Liu1, Jialu Shi1, Jinjin Zhang1, Jian-Piao Cai1, Anna Jinxia Zhang1,3, Jie Zhou1,3, Feifei Yin6,7,8, Shuofeng Yuan1,2,3, Bao-Zhong Zhang9, Hin Chu1,2,3,✉

1. State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, and Carol Yu Centre for Infection, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
2. Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, People's Republic of China.
3. Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.
4. Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
5. Guangzhou Laboratory, Guangdong Province, China.
6. Academician Workstation of Hainan Province, Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Hainan Medical University, Haikou, Hainan, People's Republic of China and The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
7. Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, Haikou, Hainan, China.
8. Department of Pathogen Biology, Hainan Medical University, Haikou, Hainan, China.
9. CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; Shenzhen, People's Republic of China.
*These authors contributed equally to this work as first authors

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Yuen TTT, Chan JFW, Yan B, Shum CCY, Liu Y, Shuai H, Hou Y, Huang X, Hu B, Chai Y, Yoon C, Zhu T, Liu H, Shi J, Zhang J, Cai JP, Zhang AJ, Zhou J, Yin F, Yuan S, Zhang BZ, Chu H. Targeting ACLY efficiently inhibits SARS-CoV-2 replication. Int J Biol Sci 2022; 18(12):4714-4730. doi:10.7150/ijbs.72709. Available from https://www.ijbs.com/v18p4714.htm

File import instruction

Abstract

Graphic abstract

The Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the biggest public health challenge the world has witnessed in the past decades. SARS-CoV-2 undergoes constant mutations and new variants of concerns (VOCs) with altered transmissibility, virulence, and/or susceptibility to vaccines and therapeutics continue to emerge. Detailed analysis of host factors involved in virus replication may help to identify novel treatment targets. In this study, we dissected the metabolome derived from COVID-19 patients to identify key host factors that are required for efficient SARS-CoV-2 replication. Through a series of metabolomic analyses, in vitro, and in vivo investigations, we identified ATP citrate lyase (ACLY) as a novel host factor required for efficient replication of SARS-CoV-2 wild-type and variants, including Omicron. ACLY should be further explored as a novel intervention target for COVID-19.

Keywords: COVID-19, metabolomics, ACLY, SARS-CoV-2, Delta, Omicron